Arête Therapeutics Inc. (the “Company”) is discovering and developing ‘first in class’ small molecule drugs directed at novel targets for cardiovascular diseases and inflammation. The Company’s proprietary therapies are directed at a new branch of arachidonic acid metabolism, which is a proven (US $10+B) pathway for therapeutic intervention in a variety of inflammatory diseases. Arête’s technology is based on a portfolio of issued and pending patents resulting from over two decades of research by Dr. Bruce Hammock (Distinguished Professor and Scientific Founder) at the University of California at Davis. The
Company has a series of proprietary molecules with preclinical efficacy in various animal models of hypertension, renal and lung inflammation. An IND candidate from this series will be selected in 1H06 for progression into Phase Ia/Ib clinical development in 1H07.